ACCENDRA HEALTH INC/VA/ ACH revenue by segment, product and geography
In its fiscal year ending 2025-12-31, ACCENDRA HEALTH INC/VA/ reported revenue across 7 products and services; the largest, Diabetes Product, was $783M, 28.4% of the filed sum (+0.8% against the prior period in the same filing).
Reported segment mix
figures as filed · share of the filed sum · change vs the prior period in the same filing- Diabetes Product$783M28.4%+0.8% yoy
- Sleep Therapy Product$740M26.8%+5.3% yoy
- Home Respiratory Therapy Product$433M15.7%-0.7% yoy
- Product And Service Other$288M10.4%+7.4% yoy
- Ostomy$213M7.7%+8.6% yoy
- Wound Care$189M6.8%-2.0% yoy
- Urology$116M4.2%+8.3% yoy
Members sum to the consolidated $2.76B for this period.
- Diabetes Product$186M29.6%-0.8% yoy
- Sleep Therapy Product$167M26.6%-8.2% yoy
- Home Respiratory Therapy Product$97.2M15.5%-10.5% yoy
- Product And Service Other$57.4M9.1%-20.1% yoy
- Ostomy$51.3M8.2%+3.7% yoy
- Wound Care$39.4M6.3%-15.5% yoy
- +1 more member in the filing
Change is against the same quarter a year earlier, as reported in the same 10-Q.
Source: SEC DERA Financial Statement and Notes data sets. Dimensional XBRL facts on the business-segment, product/service and geographic axes; the engine keeps the accession of every figure. Descriptive and educational, not advice.
About these figures
Companies tag segment, product and geographic revenue as dimensional XBRL facts in their 10-K and 10-Q filings. The SEC publishes those facts in its DERA Financial Statement and Notes data sets; TrendNalysis ingests each monthly file and serves the facts exactly as filed, keyed to the accession of the filing. Shares are of the filed sum. Where a filer tags more than one breakdown on one axis, the sum exceeds consolidated revenue and no shares are computed; where the members do not add up to the consolidated figure, the residual is stated rather than hidden. Missing is never zero.
Descriptive and educational; not investment advice. Methodology and data lineage.